These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Epstein M Nephrol Dial Transplant; 2003 Oct; 18(10):1984-92. PubMed ID: 13679471 [No Abstract] [Full Text] [Related]
5. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? Haller H; Bertram A; Stahl K; Menne J Curr Hypertens Rep; 2016 Apr; 18(5):41. PubMed ID: 27115525 [TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Bauersachs J; Jaisser F; Toto R Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026 [No Abstract] [Full Text] [Related]
7. How is the heart best protected in chronic dialysis patients?: Is there life in the old drugs yet? Mineralocorticoid receptor antagonism for cardiovascular prevention in chronic dialysis patients. Mark PB; Taylor AH; McQuarrie EP; Jardine AG Semin Dial; 2014; 27(4):328-32. PubMed ID: 24499322 [No Abstract] [Full Text] [Related]
8. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Epstein M Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154 [TBL] [Abstract][Full Text] [Related]
9. Is there a new dawn for selective mineralocorticoid receptor antagonism? Luther JM Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues. Georgianos PI; Sarafidis PA; Liakopoulos V; Balaskas EV; Zebekakis PE J Clin Hypertens (Greenwich); 2016 Mar; 18(3):197-9. PubMed ID: 26456776 [No Abstract] [Full Text] [Related]
12. [Role of aldosterone in oxidative stress and renal injury]. Nishiyama A; Kusaka T; Kitajima H Yakugaku Zasshi; 2007 Sep; 127(9):1331-7. PubMed ID: 17827915 [TBL] [Abstract][Full Text] [Related]
13. New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. Narayan H; Webb DJ Curr Hypertens Rep; 2016 Apr; 18(5):34. PubMed ID: 27072827 [TBL] [Abstract][Full Text] [Related]
14. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. Patrono C; Volpe M Eur Heart J; 2021 Jan; 42(1):14-15. PubMed ID: 33428718 [No Abstract] [Full Text] [Related]
15. [Antifibrotic renal role of mineralcorticoid receptor antagonists]. Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464 [TBL] [Abstract][Full Text] [Related]